Skip to main content

Table 3 Predictors of the number of serotypes (0–12) with positive antibody response, i.e., ≥ 2-fold increase from prevaccination serotype-specific [IgG], after prime-boost vaccination

From: Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients

  Stepwise selection of exposure variables, p of likelihood ratio test Multivariate linear regression model
Predictors: 1 2 3 4 Coefficient estimate 95% CI p
Intercept (control)      11.2 10.3, 12.1 < 0.001
Rituximab (yes/no) < 0.001 < 0.001 < 0.001 < 0.001 − 8.6 − 9.8, − 7.4 < 0.001
Abatacept (yes/no) 0.008 0.009 0.009 0.007 − 1.9 − 3.2, − 0.6 0.005
cDMARD (yes/no) < 0.001 < 0.001 < 0.001 < 0.001 − 1.8 − 2.8, − 0.8 < 0.001
Gender 0.11 0.13 0.13 0.10 Goodness of fit: multiple R2 = 0.69
Age (years) 0.59
CRP (mg/L) 0.38 0.39 0.36
Prednisolone dose (mg/day) 0.56 0.63
\